FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 900 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... February 8, 2024 Pediatricians’ Offices Can Help Parents Quit Smoking, Study Shows September 12, 2019 FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma April 14, 2021 What Are Patient-Reported Outcomes and Why Are They Important in Cancer... June 29, 2023 Load more HOT NEWS What to Know About Getting Access to New Cancer Advances Presented... EMA Recommends Granting a Marketing Authorisation for Generic Eribulin Όροι χρήσης και προϋποθέσεις 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected...
